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Filaggrin breakdown products determine corneocyte
conformation in patients with atopic dermatitis
Christoph Riethmuller, PhD,a* Maeve A. McAleer, MRCP,b,c* Sjors A. Koppes, MD,d Rawad Abdayem, MSc,e
Jonas Franz,a Marek Haftek, MD, PhD,e Linda E. Campbell, MSc,f Stephanie F. MacCallum, BSc,f W. H. IrwinMcLean, PhD,
DSc, FRS, FRSE, FMedSci,f Alan D. Irvine, MD,b,c,f,g and Sanja Kezic, PhDd Munster, Germany, Dublin, Ireland,
Amsterdam, The Netherlands, Lyon, France, and Dundee, United KingdomBackground: Loss-of-function (LOF) mutations in the filaggrin
gene (FLG) are a well-replicated risk factor for atopic dermatitis
(AD) and are known to cause an epidermal barrier defect. The
nature of this barrier defect is not fully understood. Patients with
AD with FLG LOF mutations are known to have more persistent
disease,more severe disease, and greater risk of food allergies and
eczema herpeticum. Abnormalities in corneocyte morphology
have been observed in patients with AD, including prominent
villus-like projections (VP); however, these ultrastructural
features have not been systematically studied in patients with AD
in relation to FLG genotype and acute and convalescent status.
Objective: We sought to quantitatively explore the relationship
between FLG genotype, filaggrin breakdown products (natural
moisturizing factor [NMF]), and corneocyte morphology in
patients with AD.
Methods: We studied 15 children at first presentation of AD and
after 6 weeks of standard therapy. We applied atomic force
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methodology, the number of VPs per investigated corneocyte area
was assessed and expressed as the Dermal Texture Index score.
Corneocytes were also labeled with an anti-corneodesmosin
antibody and visualized with scanning electron microscopy.
Results: We found a strong correlation between NMF levels and
Dermal Texture Index scores in both acute and convalescent
states (respective r 5 20.80 and 20.75, P < .001 and P 5 .002).
Most, but not all, VPs showed the presence of corneodesmosin
abundantly all over the cell surface in homozygous/compound
heterozygous FLG patients and, to a lesser extent, in
heterozygous and wild-type patients.
Conclusions: NMF levels are highly correlated with corneocyte
morphology in patients with AD. These corneocyte
conformational changes shed further insight into the filaggrin-
deficient phenotype and help explain the barrier defect in
patients with AD with FLG LOF mutations. (J Allergy Clin
Immunol 2015;136:1573-80.)
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A recent study using scanning electron microscopy (SEM)
showed abnormal surface structures of corneocytes from patients
with atopic dermatitis (AD) that the authors named as villus-like
projections (VPs).1 Similar structures were described as protru-
sions2 and rough corneocytes.3 Bead- or nipple-like elevations
have also been observed in abdominal,4 cheek, and plantar cor-
neocytes,5 as well as in 2,4,6-trinitro-1-chlorobenzene–sensitized
hairless mice.6 They seem to be absent in forearm healthy skin2 or
exclusively present in the periphery of corneocytes from the inner
upper arm.5 A villous appearance with an irregular fine nodular
surface pattern has also been shown in patients with ichthyosis
vulgaris and in squamous cells from patients with psoriasis.7 In
most of these studies, VPs were observed qualitatively, and
only in one study were the VPs determined semiquantitatively,5
suggesting a correlation between VP numbers and skin barrier
function, as assessed based on transepidermal water loss
(TEWL). The nature and cause of VPs on the stratum corneum
(SC) surface is not well understood. Several mechanistic
suggestions have been proposed for the occurrence of VPs,
including disturbed organization of the cytoskeleton on
desmosome disruption, immature and fragile cornified envelopes
(CEs), and attachment sites of desmosomes.1,2,6,8 Rankl et al4
showed that staining for corneodesmosin protein mostly matched
the beadlike topographic features, although not all of these
structures showed corneodesmosin immunoreactivity.1573
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1574 RIETHMULLER ET ALAbbreviations usedAD: Atopic dermatitisAFM: Atomic force microscopyCE: Cornified envelopeDTI: Dermal Texture IndexFLG: Filaggrin geneLOF: Loss of functionNMF: Natural moisturizing factorSC: Stratum corneumSEM: Scanning electron microscopyTEWL: Transepidermal water lossVP: Villus-like projectionBecause filaggrin (gene name FLG) is a component of the CE9
and filaggrin-deficient corneocytes display gene dose-dependent
alterations in CE structure,10 we aimed to investigate the relation-
ship between VPs on the SC with levels of filaggrin degradation
products in children with AD. The filaggrin degradation products
histidine, pyrrolidone-5-carboxylic acid, and urocanic acid can be
used as an indirect measure of filaggrin expression that is depen-
dent not only on FLG loss-of-function (LOF) mutations but also
on other factors, including genetic factors, filaggrin degradation
pathway factors,11 and both local and systemic inflammation.12,13
Furthermore, because these products are the main source of the
constituents of natural moisturizing factor (NMF) and contribute
to SC hydration, their levels might influence structural conforma-
tion of the CE.
In this study we used high-resolution atomic force microscopy
(AFM) to investigate the topography of corneocytes in patients
with AD in relation to FLG genotype and levels of filaggrin
degradation products. AFM provided nanoscale 3-dimensional
resolution of native corneocytes collected by means of adhesive
tape stripping. AFM involves a sharp tip at the end of a soft silicon
cantilever touching and scanning the surface of a sample. Because
of the change in topography, the deflection of the cantilever is
transformed into a 3-dimensional image. Recently, we have
developed and evaluated a software method through which VP
surfaces on the corneocyte can be quantitatively determined
(the Dermal Texture Index [DTI]; technical manuscript in prepa-
ration, full details available on request from the authors [CR]).We
measured DTI scores in corneocytes of children with active AD at
first presentation and after 6 weeks of standard topical therapy
with skin care regimens and appropriate topical steroids. In addi-
tion to DTI scores, we measured NMF levels; skin barrier func-
tion, as assessed based on TEWL; and severity of AD based on
the SCORAD score.14 Next, we investigated the distribution of
corneodesmosome remnants by using SEM and corneodesmosin
immunocytochemical labeling.METHODS
Study population
Patients with AD were recruited from a dedicated AD clinic in a tertiary
referral center. An experienced pediatric dermatologist (ADI, MAM, or both)
made the diagnosis and recorded the disease phenotype. All patients met the
United Kingdom diagnostic criteria15 and had moderate or severe disease.
Exclusion criteria from the study included patients who had pyrexial illness
in the preceding 2 weeks; those who had received immunosuppressive sys-
temic therapy, such as oral corticosteroids, in the preceding 3 months; and
those whose ancestry was not exclusively Irish (4/4 grandparents). The study
was conducted in accordance with the Helsinki Declarations and wasapproved by the Research Ethics Committee of Our Lady’s Children’s
Hospital, Dublin, Ireland. Full written informed consent was obtained from
all patients’ parents. The children were treatment naive at presentation and
were assessed at first presentation and after 6 weeks of standard treatment
with skin care regimens and appropriate topical steroids.
Severity assessment
The severity of a patient’s AD was assessed by using the SCORAD index.
A single dermatologist performed all SCORAD measurements. SCORAD is
one of the most valid and reliable instruments to assess the clinical severity of
AD.16 SCORAD is a composite score on a scale of 0 to 103 that incorporates
both objective physicians’ estimates of extent and severity and subjective
patient or parental assessments of itch and sleep loss.17 SCORAD is internally
consistent, responsive, and interpretable and has adequate interobserver
reliability (Cohen k 5 0.82, P < .001).18
Biophysical measurements of the SC
All topical therapies, including emollients,werewithheld from the patients’
upper limbs for 48 hours before skin biophysical measurements were
performed. All measurements were done in standardized environmental
conditions (room temperature, 228C to 258C; humidity levels, 30% to 35%).
Before testing, the patient’s forearm was acclimatized to this controlled
environment for aminimumof 10minutes.Allmeasurementswere done by the
same investigator and on a clinically unaffected area of skin on the volar
forearm. TEWL was determined by using a Tewameter 300 (Courage and
Khazaka Electronic GmbH, Cologne, Germany).
Sampling of the SC by using tape stripping
The SC was sampled by using the previously described method.19
A clinically unaffected site on the patient’s volar forearm, where the TEWL
measurement was also taken, was used for SC sampling. Circular adhesive
tape strips (3.8 cm2, D-Squame; Monaderm, Monaco, France) were attached
to volar forearm skin and pressed for 10 seconds with a constant pressure
(225 g/cm2) by using a D-Squame Pressure Instrument D500 (CuDerm,
Dallas, Tex). The tape strip was then gently removed and placed in a closed
vial. Eight consecutive tape strips were sampled, all from the same site. The
tape strips were immediately stored at 2808C until analysis.
FLG genotyping
All patients were screened for the 9 most common FLGmutations found in
the Irish population (R501X, Y2092X, 2282del4, R2447X, S3247X, R3419X,
3702X, S1040X, and G1139X) fromDNA extracted from a blood sample. The
methods used have been previously described.20
NMF determination
NMF analysis was performed on the fifth consecutive strip, according to
methods described in detail elsewhere.19 Briefly, each tape strip was extracted
with 25% (wt/wt) ammonia solution. After evaporation of the ammonia
extract, the residuewas dissolved in 250 mL of pure water and analyzed by us-
ing HPLC. The NMF concentration was normalized for the protein amount
determined with a Pierce Micro BCA protein assay kit (Thermo Fischer
Scientific, Rockford, Ill; referred to as the Pierce assay) to compensate for a
variable amount of the SC on the tape.Skin nanotexture analysis (DTI)
Corneocytes from patients were analyzed with AFM, as previously
described.21 Briefly, in each case the seventh tape strip was subjected to
AFM measurements carried out with a Multimode AFM equipped with the
Nanoscope III controller and software version 5.30sr3 (Digital Instruments,
Santa Barbara, Calif). Silicon-nitride tips on V-shaped gold-coated cantilevers
were used (0.01 N/m, MLCT; VEECO, Mannheim, Germany). Imaging was
performed at ambient temperature with forces of less than 1 nN and 1 to 3
scan lines per second (1-3 Hz) with 512 3 512 pixel resolution. For texture
TABLE I. Demographic data of patients, DTI scores, and NMF levels assessed at baseline (treatment naive) and after 6 weeks of
treatment
Sex Age (mo) No. of FLG mutations
SCORAD score TEWL (g/m2 h) DTI score (AU) NMF (mmol/g)
Week 0 Week 6 Week 0 Week 6 Week 0 Week 6 Week 0 Week 6
M 9.3 0 28.9 22.5 12.7 14.1 172.0 139.8 0.41 0.63
M 5.3 0 62.5 14.6 27.1 12.9 434.4 172.7 0.26 0.32
M 5 0 27.9 4.5 27.3 11.6 397.5 208.2 0.24 0.75
M 9 0 53.5 59.3 17 15.1 411.2 363.5 0.37 0.31
M 9.5 0 26.9 21.8 13.8 8.8 265.8 237.3 0.41 0.47
M 8.5 0 47.4 17.9 14.5 13.6 173.4 185.7 0.43 0.29
M 2.3 1 42.1 20.3 13.1 12.7 170.1 249.3 0.25 0.26
F 57.3 1 38.5 24.6 11.5 7.7 122.5 116.3 0.43 0.52
M 10 1 55.1 20.9 14.9 8.3 660.6 96.3 0.19 0.65
F 6 1 57.1 8.2 15.9 14.6 623.0 421.0 0.25 0.28
M 6.25 1 35.3 56.6 13.4 10.7 259.1 219.9 0.30 0.19
M 8.25 1 28.6 9.2 13.7 13.4 372.8 196.3 0.33 0.38
M 6.8 2 70.5 66.2 41.6 22.3 412.4 617.3 0.11 0.18
M 28 2 61.2 28.1 22.8 14.7 822.5 496.8 0.06 0.11
M 5.75 2 42 13.1 34.4 25.4 653.8 367.2 0.13 1*
F, Female; M, male.
*Analysis failed.
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were analyzed from each sample.
Topographic cell-surface data were analyzed with the nAnostic method,
applying custom-built proprietary algorithms (Serend-ip GmbH, Munster,
Germany). The principle of this method has been described elsewhere.22
Briefly, each nanostructure protruding from the mean surface level was
morphometrically evaluated. These objects were then filtered by size and
shape through computer vision. At this stage, only structures of positive local
deviational volume smaller than 500 nm in height and with an area of less than
1 mm2 were considered. The DTI score is the count of identified objects per
image (a mean value from 10 randomly recorded images).Corneodesmosin immunolabeling
Corneocytes from 3 patients with different FLG mutation genotypes
collected on D-squame discs were labeled with an anti-corneodesmosin
antibody and visualized with SEM, as described elsewhere.23 Briefly, the
native cells exposed to the mouse mAb to corneodesmosin (diluted 1:100;
Abnova, Jhongli City, Taiwan) were immunogold labeled with the goat anti-
mouse Ultra Small probe (0.8 nm, diluted 1:10; Aurion, Wageningen, The
Netherlands). The labeling was silver enhanced with the BBI kit (BBI
Solutions, Cardiff, United Kingdom), and the samples, after dehydration in
ethanol, were observed in a partial vacuum by using secondary and backscat-
tered electron detection modes.Statistics
Data were checked for normality by using the Shapiro-Wilk test. The
relationship between DTI scores and clinical parameters was tested either by
using the Pearson correlation test or Spearman rank correlation if the variables
were not normally distributed or the relationship between the variableswas not
linear. Because of skewed distribution, DTI scores and NMF levels were log-
transformed before linear regression analysis. Differences in the investigated
parameters (DTI score, TEWL, SCORAD score, and NMF level) between 2
measurement points (0 and 6 weeks) were tested by using the paired 2-sided t
test (NMF and DTI score) or by using the Wilcoxon matched signed-rank test
in the case of deviation from normal distribution (TEWL and SCORAD
score). Differences in DTI scores among 3 FLG genotypes were tested by
using the Kruskal-Wallis test, followed by Dunn multiple comparison. The
relationship between the DTI score as a dependent variable versus the
SCORAD score and NMF level as dependent variables was tested by using
a linear regression model with SPSS software (version 22; IBM, Somers,
NY). For other statistical analyses, GraphPad Prism version 5.00 softwarefor Windows (GraphPad Software, San Diego, Calif) was used. A P value
of less than .05 was considered statistically significant.RESULTS
Demographic characteristics of the investigated populations
and values of measured parameters are presented in Table I. Fig 1
shows representative AFM images of the surfaces of corneocytes
sampled from patients with AD with 3 different FLG mutation
genotypes. On simple inspection, VP numbers were clearly
increased in carriers of FLG mutations. The DTI score, which
quantifies the number of VPs per investigated surface area,
showed a trend toward higher mean values in the carriers of
FLG mutations compared with FLG wild-type subjects at week
0 (427.0 and 336.2, respectively) and after 6 weeks of therapy
(296.6 and 224.3, respectively), although the differences did not
reach statistical significance (data not shown). At week 6, howev-
er, the DTI in the FLG2/2 group was significantly higher than in
the FLG1/1 group (respective median values were 496.8 and
208.2, respectively; P < .05, as assessed by using the 2-tailed
Mann-Whitney test), whereas there was no significant difference
in SCORAD scores between these 2 FLG genotype groups. When
DTI scores were plotted against the NMF levels, a significant
correlation was observed at both weeks 0 and 6 (respective
correlation coefficients amounted to 20.80 and 20.75, P < .001
and P5 .002, respectively; Fig 2, A). VP numbers reach a plateau
at normal NMF levels (approximately 0.5 mmol/g protein).
Regression analysis of log-transformed values of DTI scores
and NMF levels showed almost identical regression coefficients
for 0 and 6 weeks (20.726 and 20.730, respectively; Fig 2, B).
The relationship of DTI scores with TEWL and SCORAD
scores (see Fig E1 in this article’s Online Repository at
www.jacionline.org) was weaker than that of DTI scores and
NMF levels. Furthermore, in a linear regression model with the
DTI score as a dependent variable versus the NMF level and
SCORAD score, only NMF levels showed a significant effect
on DTI scores (P 5 .005 and .015, respectively, for weeks
0 and 6; see Table E1 in this article’s Online Repository at
www.jacionline.org).
FIG 1. Representative AFM images of the surfaces of corneocytes sampled from patients with AD with 3
different FLG mutation genotypes: 1/1, wild-type homozygote; 1/2, heterozygote for FLG LOF mutation;
2/2, compound heterozygote or homozygote for FLG LOF mutation. On simple inspection, numbers of
VPs were clearly increased in carriers of FLG mutations.
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scores measured at the first presentation of disease and after
6 weeks of standard topical therapy with skin care regimens and
appropriate topical steroids are shown in Table I and Fig 3.
Although the skin barrier, as measured based on TEWL and
SCORAD scores, significantly improved after 6 weeks of therapy,
NMF levels and DTI scores did not mirror these improvements in
all patients.
Representative SEM images of D-Squames after immunogold
labeling are shown in Fig 4 for 3 patients with AD of different
FLG genotype status. The high abundance of VPs on the
corneocytes obtained from an FLG2/2 subject (Fig 4, C) was
confirmed by means of SEM. The VPs were decorated at their
tips with corneodesmosin labeling, indicating the presence of dis-
rupted corneodesmosome structures (Fig 4, D). The corneocytes
of a homozygous subject (FLG2/2) demonstrated labeling over
the entire surface (Fig 4, C). In contrast, in a patient who is
wild-type with respect to FLG mutations (FLG1/1; Fig 4, A),
the labeling was almost exclusively distributed on the lateral
rims of the cell. In the heterozygous patient (FLG1/2; Fig 4, B)the central area of corneocytes remained largely free of the label,
even though it was partially occupied by the VPs (Fig 4, B,
arrows).DISCUSSION
Filaggrin deficiency results in a definite skin barrier defect, but
the pathomechanisms underlying this defect are poorly under-
stood.11Within the corneocytes, filaggrin aggregates intermediate
keratin filaments that are linked to the corneodesmosomes, which
interconnect the corneocytes, providing a physical barrier
structure at the top of the skin.24,25 Together with keratin
filaments, filaggrin has been proposed to provide a scaffold for
the assembly of structural proteins, such as involucrin, loricrin,
and small proline-rich proteins, which are cross-linked by several
transglutaminases to form the CE.24,25 Some CE proteins serve as
an anchor for attachment of ceramides, and thus lack of filaggrin
might also affect the structural organization of the intercellular
SC lipid lamellae responsible for barrier function.
FIG 2. A, Relationship between DTI scores andNMF levels at first presentation of disease (squares) and after
6 weeks of topical therapy with skin care regimens and appropriate topical steroids (circles), with
corresponding correlation coefficients (r). B, Linear regression analysis of log-transformed DTI scores
and NMF levels at first presentation of disease (squares) and after 6 weeks of topical therapy with skin
care regimens and appropriate topical steroids (circles)., B, Patients with AD wild-type with respect to
FLG LOF mutations;J,3, patients with AD heterozygous for FLG LOF mutations; 5@, patients with AD
homozygous or compound heterozygous for FLG LOF mutations.
FIG 3. TEWL, SCORAD score, DTI score, and NMF level at first presentation of disease and after 6 weeks of
topical therapy with skin care regimens and appropriate topical steroids.
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is associated with altered topography of the corneocyte surface,
likely caused by defects in the CE. In a recent study2 similar
villous structures were observed on the palmar skin of healthy
subjects, although not on forearm skin, which is in contrast to
the present study. We found that levels of filaggrin degradation
products (NMF) used as a marker of filaggrin expression12,26
were strongly associated with corneocyte VP numbers. These
corneocytes were sourced from the upper middle part of the SC
(seventh strip); however, the same pattern concerning distribution
of VPs was also seen in the more superficial strips (eg, strip
number 4; data not shown). VP numbers were more closelyrelated to NMF levels than to SCORAD scores, suggesting that
the absence of filaggrin is important for the formation of VPs
rather than inflammation per se. This is supported by similar
regression coefficients of the DTI score versus NMF level rela-
tionship at weeks 0 and 6, despite the sharp decrease in SCORAD
scores. Furthermore, in a linear regression model with the DTI
score as a dependent variable versus the NMF level and SCORAD
score as independent variables, only NMF levels showed a
significant effect on DTI scores at both weeks 0 and 6. Local
inflammation might have affected the presence of DTI scores
indirectly by influencing NMF levels, an effect that previously
has been shown in vitro and in vivo.12,13 This might explain the
FIG 4. SEM immunolabeling of corneodesmosin. A, Corneodesmosomes at the cell surface of a patient
wild-type with respect to FLG LOF mutations (FLG1/1). B, A patient heterozygous for FLG LOF mutations
(FLG1/2). C, A patient homozygous for FLG LOF mutations (FLG2/2). Insert in Fig 4, C, Corneodesmosin-
expressing junctions present at the tops of the VPs in the patient homozygous for FLG LOF mutations. Ar-
rows in Fig 4, B, show the presence of VPs (not labeled for corneodesmosin).
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with AD with FLG LOF mutations and patients with AD without
FLG LOF mutations, although the former group tended to have
higher DTI scores, and the lack of statistical significance seen
here might simply be due to a lack of power in this study. Further-
more, at week 6, the FLG2/2 patients, in whom inflammation is
controlled and NMF levels are mainly influenced by FLG LOF
mutations, had significantly higher DTI scores compared with
FLG1/1 patients, despite clinical improvement, as measured
based on SCORAD scores. Also of note is our observation that
the relationship between TEWL and DTI scores was significantat 6 weeks (after anti-inflammatory therapy) but not at week
0 (see Fig E1). This suggests a relationship between corneocyte
conformation as measured by DTI scores and barrier function
(TEWL).
During the transition from the stratum compactum to the
stratum disjunctum, corneocyte morphology and mechanical
properties change from a ‘‘fragile’’ and soft to a more robust,
smooth, and ‘‘rigid’’ phenotype.27-29 This transition process is
accompanied by loss of nonperipheral corneodesmosomes
because only peripheral corneodesmosome attachments connect-
ing consecutive layers of corneocytes remain.28,29 Interestingly,
J ALLERGY CLIN IMMUNOL
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surface in FLG2/2 patients, and, to lesser extent, in heterozygous
patients, which suggests changes in their maturation because of a
disturbed terminal differentiation program. As discussed by
Rawlings28 and shown by Watkinson and Rawlings,30 the loss
of nonperipheral corneodesmosomes and CE maturation changes
seem to parallel filaggrin degradation. Lack of filaggrin in the CE
and between the keratin filaments might lead to conformational
changes, and the adhesive portions of the peripheral
corneodesmosomes might become less accessible for degradation
enzymes. In addition to the direct effect of filaggrin, the existence
of VPs might also be caused by a reduction in filaggrin
degradation products and reduced hydration of the SC.
Matsumoto et al6 observed the emergence of villi on the rear
surfaces of corneocytes after topical exposure to the contact
allergen 2,4,6-trinitrochlorobenzene, which caused dry and in-
flamed skin. However, the villi disappeared after topical treatment
with a moisturizer at a higher rate than after topical corticosteroid
therapy. The surfactant-induced xerosis led to a considerable
increase of the immature and fragile CE phenotype.29 The
perturbation of CE maturation coincided with reduced hydrolysis
of corneodesmosomes, which was paralleled by altered activity of
transglutaminase. Recently, we have shown that exposure to
sodium lauryl sulfate caused a dramatic decrease in NMF levels
in the SC,31 and therefore the changes in corneocyte maturation
might have also been caused by the lack of NMF. Interestingly,
also in the study of Harding et al,29 the balance between the 2
CE phenotypes was recovered after treatment with a moisturizer,
emphasizing the importance of SC hydration for the maturation
process.
The size of the VPs (ie, several hundreds of nanometers:
average height, 350 nm; width at half-maximum, 250-400 nm)
and their high abundance is intriguing. The CE is
approximately 20 nm thick, implying that considerable
mechanical force lies behind its protrusion. The present results
do not allow firm conclusions to be drawn regarding the
relationship between VPs and retention of the nonperipheral
corneodesmosomes because the presence of VPs was not
always accompanied by central distribution of corneodesmosin.
The persistence of VPs in both the acute and convalescent
phases of AD with FLG loss-of-function mutations offers an
intriguing insight into the persistent abnormalities in ‘‘normal’’
or ‘‘unaffected’’ AD skin, an area of great interest.32 The
persistence of an underlying physical and structural abnormality,
even in light of apparent clinical improvement, might explain
why patients with AD with FLG loss-of-function mutations
have more severe and persistent disease,33 why they are more
likely to have eczema herpeticum,34 and why they have more
food allergies.35
In conclusion, we have shown for the first time a
significant structural difference in corneocytes in patients with
AD with FLG loss-of-function mutations that can be
quantitatively measured. These structural changes correlate well
with NMF levels and persist despite apparent clinical
improvement and might explain some of the observed phenotypic
differences in patients with AD with FLG loss-of-function
mutations.
The SEM images were obtained at the Centre Technologique des
Microstructures, CTm, an LBI platform of University Lyon 1.Clinical implications: Corneocytes of patients with AD with
FLG loss-of-function mutations are morphologically distinct
both in active disease and in convalescence from those of
patients withADwithoutFLGLOFmutations. These structural
differences can explain clinical differences between AD
endophenotypes and facilitate assessment of therapeutic
interventions.REFERENCES
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FIG E1. Relationship between DTI scores and clinical parameters at first presentation of disease (squares)
and after 6 weeks of topical therapy with skin care regimens and appropriate topical steroids (circles).,B,
Patients with AD with respect to FLG LOF mutations; J, 3, patients with AD heterozygous for FLG LOF
mutation; 5@, patients with AD homozygous or compound heterozygous for FLG LOF mutations.
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TABLE E1. Linear regression model for DTI score as the dependent variable and NMF level and SCORAD score as predicting
variables at baseline (treatment naive) and after 6 weeks of treatment
Coefficients*
Model
Unstandardized
coefficients Standardized coefficients
t Significance (P value)B SE b
Baseline*
1 (constant) 680.806 222.435 3.061 .010
NMF0 21292.165 375.588 20.729 23.440 .005
SCORAD0 1.664 3.159 0.112 0.527 .608
After 6 wk of treatment
1 (constant) 470.605 78.408 6.773 .000
NMF6 2514.723 178.133 20.654 23.012 .015
SCORAD6 20.200 0.560 20.081 20.314 .727
DTI0, DTI score at o weeks; DTI6, DTI score at 6 weeks; NMF0, NMF level at 0 weeks; NMF6, NMF level at 6 weeks; SCORAD0, SCORAD score at 0 weeks; SCORAD6,
SCORAD score at 6 weeks.
*The dependent variable is DTI0, and predictors (constant) are SCORAD0 and NMF0.
The dependent variable is DTI6, and predictors (constant) are SCORAD6 and NMF6.
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